MediXall (MDXL) Liabilities and Shareholders Equity (2019 - 2024)
MediXall's Liabilities and Shareholders Equity history spans 8 years, with the latest figure at $219980.0 for Q3 2024.
- For Q3 2024, Liabilities and Shareholders Equity fell 51.71% year-over-year to $219980.0; the TTM value through Sep 2024 reached $922145.0, down 62.01%, while the annual FY2023 figure was $201103.0, 76.67% down from the prior year.
- Liabilities and Shareholders Equity reached $219980.0 in Q3 2024 per MDXL's latest filing, down from $229333.0 in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.3 million in Q1 2021 to a low of $201103.0 in Q4 2023.
- Average Liabilities and Shareholders Equity over 5 years is $900719.4, with a median of $941376.5 recorded in 2022.
- Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 75.21% in 2020, then plummeted 76.67% in 2023.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $1.6 million in 2020, then tumbled by 31.15% to $1.1 million in 2021, then dropped by 23.82% to $862013.0 in 2022, then tumbled by 76.67% to $201103.0 in 2023, then increased by 9.39% to $219980.0 in 2024.
- Per Business Quant, the three most recent readings for MDXL's Liabilities and Shareholders Equity are $219980.0 (Q3 2024), $229333.0 (Q2 2024), and $271729.0 (Q1 2024).